Treatment for early prostate cancer associated with type of specialist seen
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive. The study, co-led by a urologist and a radiation oncologist at Memorial Sloan-Kettering Cancer Center, found that patients aged 65 to 69 years old who consult a urologist are more likely to undergo surgery to remove the prostate, while those who consult a radiation oncologist and a urologist, regardless of age, usually receive radiation therapy.
Herceptin does not increase heart failure in patients long-term
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy. Their findings will be announced at the Women’s Cancers press briefing at the meeting and published in Abstract LBA513 in the ASCO proceedings. more
Nonhormonal drug reduces hot flashes in men treated for prostate cancer
North Central Cancer Treatment Group researchers based at Mayo Clinic in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer. more
Brain-boosting pill alleviates post-chemotherapy fogginess
A drug described by some people as a “genius pill” for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as “chemo-brain,” according to a University of Rochester Medical Center study. more
MRI detects cancers missed by mammography in breast cancer patients
A unique examination of one treatment center’s use of magnetic resonance imaging (MRI) in new breast cancer patients has found MRI to be superior to mammography in finding additional tumors in a breast in which cancer has already been diagnosed, and in detecting new tumors in a patient’s supposedly healthy breast.
Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center. more
Exploring better ways to determine when to change the course of treatment
Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help doctors determine when or if a change in treatment should be made. The results of a large, multicenter, international study laying the groundwork for such decisions were presented today at the Annual Meeting of the American Society of Clinical Oncology. The study showed the number of circulating tumor cells, or CTC, is a significant predictor of survival and cancer progression. more
© Vidyya. All rights reserved.